
Peng-Fei Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6741072/publications.pdf Version: 2024-02-01



PENC-FEI WANC

#	Article	IF	CITATIONS
1	Organocatalytic atroposelective construction of axially chiral N, N- and N, S-1,2-azoles through novel ring formation approach. Nature Communications, 2022, 13, 1933.	12.8	28
2	Atroposelective Construction of Nineâ€Membered Carbonateâ€Bridged Biaryls. Angewandte Chemie, 2022, 134, .	2.0	12
3	Atroposelective Construction of Nineâ€Membered Carbonateâ€Bridged Biaryls. Angewandte Chemie - International Edition, 2022, 61, .	13.8	33
4	Organocatalytic Asymmetric Construction of Tetrasubstituted Carbon Stereocenters Bearing Three Heteroatoms via Intramolecular Cyclization of Vinylidene <i>ortho</i> -Quinone Methide with Imidates. Organic Letters, 2022, 24, 5073-5077.	4.6	4
5	A patent review of mTOR inhibitors for cancer therapy (2011–2020). Expert Opinion on Therapeutic Patents, 2021, 31, 1-11.	5.0	8
6	Organocatalytic Enantioselective Construction of Chiral Azepine Skeleton Bearing Multiple‧tereogenic Elements. Angewandte Chemie - International Edition, 2021, 60, 21486-21493.	13.8	55
7	Organocatalytic Enantioselective Construction of Chiral Azepine Skeleton Bearing Multipleâ€ S tereogenic Elements. Angewandte Chemie, 2021, 133, 21656-21663.	2.0	15
8	Organocatalytic cascade reactions for multi-functionalized chiral cyclic ethers through vinylidene <i>ortho</i> -quinone methides. Chemical Communications, 2021, 57, 11334-11337.	4.1	9
9	From Methaqualone and Beyond: Structure–Activity Relationship of 6-, 7-, and 8-Substituted 2,3-Diphenyl-quinazolin-4(3 <i>H</i>)-ones and in Silico Prediction of Putative Binding Modes of Quinazolin-4(3 <i>H</i>)-ones as Positive Allosteric Modulators of GABA _A Receptors. ACS Chemical Neuroscience, 2020, 11, 4362-4375.	3.5	7
10	Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 – 2019). Expert Opinion on Therapeutic Patents, 2020, 30, 795-805.	5.0	7
11	A patent review of BRAF inhibitors: 2013-2018. Expert Opinion on Therapeutic Patents, 2019, 29, 595-603.	5.0	8
12	Design, synthesis, and biological evaluation of new B-RafV600E kinase inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 2372-2380.	3.0	11
13	Design of potent Bâ€Raf ^{V600E} inhibitors by multiple copy simulation search strategy. Chemical Biology and Drug Design, 2018, 91, 567-574.	3.2	6
14	Naphthoquinones: A continuing source for discovery of therapeutic antineoplastic agents. Chemical Biology and Drug Design, 2018, 91, 681-690.	3.2	88
15	Identification and Biological Evaluation of Novel Type II Bâ€RafV600EInhibitors. ChemMedChem, 2018, 13, 2558-2566.	3.2	8
16	C-7 modified flavonoids as novel tyrosyl-tRNA synthetase inhibitors. RSC Advances, 2017, 7, 6193-6201.	3.6	3
17	Identification of novel B-RafV600E inhibitors employing FBDD strategy. Biochemical Pharmacology, 2017, 132, 63-76.	4.4	17
18	ldentification of new shikonin derivatives as STAT3 inhibitors. Biochemical Pharmacology, 2017, 146, 74-86.	4.4	43

Peng-Fei Wang

#	Article	IF	CITATIONS
19	Diosgenin attenuates neuropathic pain in a rat model of chronic constriction injury. Molecular Medicine Reports, 2017, 16, 1559-1564.	2.4	22
20	Shikonin derivatives as inhibitors of tyrosyl-tRNA synthetase: design, synthesis and biological evaluation. RSC Advances, 2016, 6, 83003-83010.	3.6	5
21	3-Arylpropionylhydroxamic acid derivatives as Helicobacter pylori urease inhibitors: Synthesis, molecular docking and biological evaluation. Bioorganic and Medicinal Chemistry, 2016, 24, 4519-4527.	3.0	45
22	DYT-40, a novel synthetic 2-styryl-5-nitroimidazole derivative, blocks malignant glioblastoma growth and invasion by inhibiting AEG-1 and NF-κB signaling pathways. Scientific Reports, 2016, 6, 27331.	3.3	9
23	Metronidazole containing pyrazole derivatives potently inhibit tyrosylâ€ŧRNA synthetase: design, synthesis, and biological evaluation. Chemical Biology and Drug Design, 2016, 88, 592-598.	3.2	16
24	Design, synthesis and evaluation of benzenesulfonamide-substituted 1,5-diarylpyrazoles containing phenylacetohydrazide derivatives as COX-1/COX-2 agents against solid tumors. RSC Advances, 2016, 6, 22917-22935.	3.6	12
25	Synthesis of dihydropyrazole sulphonamide derivatives that act as anti-cancer agents through COX-2 inhibition. Pharmacological Research, 2016, 104, 86-96.	7.1	38
26	Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR/HER-2 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 677-683.	2.2	54
27	Synthesis, Biological Evaluation, and Docking of Dihydropyrazole Sulfonamide Containing 2â€hydroxyphenyl Moiety: A Series of Novel <scp>MMP</scp> â€2 Inhibitors. Chemical Biology and Drug Design, 2015, 86, 1405-1410.	3.2	7
28	Synthesis, molecular docking and biological evaluation of 3-arylfuran-2(5H)-ones as anti-gastric ulcer agent. Bioorganic and Medicinal Chemistry, 2015, 23, 4860-4865.	3.0	25
29	EGFR/HER-2 inhibitors: synthesis, biological evaluation and 3D-QSAR analysis of dihydropyridine-containing thiazolinone derivatives. RSC Advances, 2015, 5, 21445-21454.	3.6	10
30	Design, synthesis and molecular docking of salicylic acid derivatives containing metronidazole as a new class of antimicrobial agents. Bioorganic and Medicinal Chemistry, 2015, 23, 6148-6156.	3.0	12
31	Synthesis and evaluation of N-analogs of 1,2-diarylethane as Helicobacter pylori urease inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 4508-4513.	3.0	17
32	Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1947-1951.	2.2	40
33	Dihydropyrazoles containing morpholine: design, synthesis and bioassay testing as potent antimicrobial agents. RSC Advances, 2015, 5, 24997-25005.	3.6	12
34	Synthesis and evaluation of new tyrosyl-tRNA synthetase inhibitors as antibacterial agents based on a N2-(arylacetyl)glycinanilide scaffold. European Journal of Medicinal Chemistry, 2015, 102, 631-638.	5.5	10
35	Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4664-4671.	2.2	24
36	Adenosine analogs as inhibitors of tyrosyl-tRNA synthetase: Design, synthesis and antibacterial evaluation. Bioorganic and Medicinal Chemistry, 2015, 23, 6602-6611.	3.0	9

Peng-Fei Wang

#	Article	IF	CITATIONS
37	Synthesis of Caffeic Acid Amides Bearing 2,3,4,5-Tetra-hydrobenzo[b][1,4]dioxocine Moieties and Their Biological Evaluation as Antitumor Agents. Molecules, 2014, 19, 7269-7286.	3.8	6
38	Novel metronidazole-sulfonamide derivatives as potent and selective carbonic anhydrase inhibitors: design, synthesis and biology analysis. RSC Advances, 2014, 4, 33029-33038.	3.6	12
39	Design and synthesis of 2-styryl of 5-Nitroimidazole derivatives and antimicrobial activities as FabH inhibitors. European Journal of Medicinal Chemistry, 2014, 76, 387-396.	5.5	16
40	Design, synthesis, evaluation and 3D-QSAR analysis of benzosulfonamide benzenesulfonates as potent and selective inhibitors of MMP-2. RSC Advances, 2014, 4, 39214.	3.6	13
41	Design, synthesis and biological evaluation of metronidazole–thiazole derivatives as antibacterial inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5279-5283.	2.2	27
42	Design, synthesis, and evaluation of novel fluoroquinolone–flavonoid hybrids as potent antibiotics against drug-resistant microorganisms. European Journal of Medicinal Chemistry, 2014, 80, 92-100.	5.5	77
43	Synthesis and biological evaluation of compounds which contain pyrazole, thiazole and naphthalene ring as antitumor agents. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2324-2328.	2.2	50
44	Novel 3-arylfuran-2(5H)-one-fluoroquinolone hybrid: Design, synthesis and evaluation as antibacterial agent. Bioorganic and Medicinal Chemistry, 2014, 22, 3620-3628.	3.0	47
45	Design, synthesis, biological evaluation and molecular docking of novel metronidazole derivatives as selective and potent JAK3 inhibitors. RSC Advances, 2014, 4, 16694-16704.	3.6	10
46	Potentiating 1-(2-hydroxypropyl)-2-styryl-5-nitroimidazole derivatives against antibacterial agents: Design, synthesis and biology analysis. European Journal of Medicinal Chemistry, 2013, 65, 456-463.	5.5	11
47	Sulfonamides containing coumarin moieties selectively and potently inhibit carbonic anhydrases II and IX: Design, synthesis, inhibitory activity and 3D-QSAR analysis. European Journal of Medicinal Chemistry, 2013, 66, 1-11.	5.5	52
48	Effect of the Combination of Fibrin Glue and Growth Hormone on Intestinal Anastomoses in a Pig Model of Traumatic Shock Associated with Peritonitis. World Journal of Surgery, 2009, 33, 567-576.	1.6	14
49	Organocatalytic atroposelective construction of axially chiral nonsymmetric biaryltriols and their applications in asymmetric synthesis and heavy metal ion detection. Organic Chemistry Frontiers, 0, , .	4.5	7